IMMX — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-07

• In May 2026, we announced that all four relapsed/refractory AL Amyloidosis MRD-negative patients presented at ASH 2025 had converted to CR). The NEXICART-2 CR rate was 95% (19 out of 20 patients). All CRs were reached within 1 year of follow-up post-dosing. No relapses have been observed to date for…

• General and administrative expense was $7,123,171 for the three months ended June 30, 2026, compared to $2,745,247 for the three months ended June 30, 2025.

• Six Months Ended June 30, 2026 compared to the Six Months Ended June 30, 2025

• General and administrative expense was $11,946,549 for the six months ended June 30, 2026, compared to $5,453,098 for the six months ended June 30, 2025.

• The expenses incurred in both periods were related to salaries, patent maintenance costs, professional fees and general accounting and other general consulting expenses, primarily related to the Company’s efforts to raise capital, increased compensation, including stock-based compensation, of $2,194…

Text removed vs the prior filing · source: 10-Q · 2026-05-07

• General and administrative expense was $4,823,378 for the three months ended March 31, 2026, compared to $2,707,851 for the three months ended March 31, 2025.

• Net cash used in operating activities was $9,817,073 for the three months ended March 31, 2026 and $1,685,140 for the three months ended March 31, 2025. Net cash used for the three months ended March 31, 2026 was primarily related to our net loss of $10,086,687, offset by non-cash items of stock-bas…

• Net cash used in financing activities in the three months ended March 31, 2026 of $37,561 was mainly related to $71,093 in payments of deferred offering costs, offset by $33,532 from cash proceeds received from the exercise of common stock options. There were no financing cash flows during the three…

Text added vs the prior filing · source: 10-Q · 2026-08-07

• Interim data from clinical trials are subject to various risks, including that final results may be materially different than those reflected in any interim data and that third parties, including regulatory agencies may disagree with the analysis used to interpret the interim data.

• Interim data from clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as more data on existing patients become available. When a clinical trial is ongoing, the final results from the trial may be materially different from those reflected in any int…

• Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization …